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Adoptive transfer of antigen-specific T lymphocytes is an effective form of immunotherapy for persistent virus 
infections and cancer. A major limitation of adoptive therapy is the inability to isolate antigen-specific T lym-
phocytes reproducibly. The demonstration that cloned T-cell receptor (TCR) genes can be used to produce 
T lymphocyte populations of desired specificity offers new opportunities for antigen-specific T-cell therapy. TCR 
gene-modified lymphocytes display antigen-specific function in vitro, and were shown to protect against virus 
infection and tumor growth in animal models. A recent trial in humans demonstrated that TCR gene-modified 
T cells persisted in all and reduced melanoma burden in 2/15 patients. In future trials, it may be possible to use 
TCR gene transfer to equip helper and cytotoxic T cells with new antigen-specificity, allowing both T-cell subsets 
to cooperate in achieving improved clinical responses. Sequence modifications of TCR genes are being explored 
to enhance TCR surface expression, while minimizing the risk of pairing between introduced and endogenous 
TCR chains. Current T-cell transduction protocols that trigger T-cell differentiation need to be modified to gen-
erate “undifferentiated” T cells, which, upon adoptive transfer, display improved in vivo expansion and survival. 
Both, expression of only the introduced TCR chains and the production of naïve T cells may be possible in the 
future by TCR gene transfer into stem cells.
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AdopTIve T-Cell TheRApy
Adoptive T-cell transfer can cure leukemia patients following 
allogeneic stem cell transplantation.1 The infused donor-derived 
T lymphocytes recognize allo-antigens expressed by leukemia 
cells, resulting in T cell–mediated leukemia killing.2 Unfortu-
nately, T cell recognized allo-antigens are also expressed in normal 
tissues which can lead to graft-versus-host disease, a condition 
where allo-reactive donor T cells attack and damage normal tis-
sues such as gut, skin and liver. Hence, the lack of specificity for 
defined tumor antigens limits the usefulness of adoptive T-cell 
therapy for the management of leukemia.
The adoptive transfer of tumor antigen-specific T cells has 
been used successfully in melanoma patients.3 Although anti-
melanoma effects were initially unimpressive, two recent devel-
opments substantially improved the clinical benefit of adoptive 
T-cell therapy in melanoma.4 First, co-transfer of CD4+ T-helper 
lymphocytes together with CD8+ cytotoxic T lymphocytes (CTL) 
was found to be more effective than previous protocols using only 
CD8+ CTL. Second, conditioning of patients is now used to cre-
ate a lymphopenic environment that favors the engraftment and 
expansion of adoptively transferred T cells. While T-cell transfer 
into normal recipients typically resulted in poor T-cell survival 
and persistence, transfer into lymphopenic hosts leads to sub-
stantial expansion and long-term survival of injected T cells. The 
combination of conditioning and transfer of CD4+ and CD8+ 
T cells resulted in disease control in approximately 50% of mela-
noma patients, an impressive clinical response rate that probably 
cannot be achieved with alternative therapy options.5
Adoptive T-cell therapy is also effective in the management 
of latent infection by Epstein-Barr virus and cytomegalie virus in 
immuno-suppressed individuals.6–13 In immuno-competent indi-
viduals, latent Epstein-Barr virus and cytomegalie virus infection 
is well tolerated as antigen-specific T cells efficiently control virus 
load. In contrast, the break down of T-cell surveillance, often seen 
after allogeneic stem cell or solid organ transplantation, is associ-
ated with a high risk of virus reactivation and the development of 
clinical symptoms such as Epstein-Barr virus-driven lymphopro-
liferative disorders and cytomegalie virus disease. In this case, the 
transfer of relatively small numbers of virus-specific donor T lym-
phocytes can reverse disease progression and establish long-term 
protection.
The inability to generate antigen-specific T cells is a serious 
limitation of adoptive T-cell therapy of cancer. Tumor antigens are 
often poorly immunogenic and patients are frequently immuno-
compromised as a consequence of tumor burden or as a side 
effect of radiation treatment and chemotherapy. In a similar way, 
adoptive T-cell therapy of Epstein-Barr virus and cytomegalie 
virus is typically based on the isolation of virus-specific T cells 
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from latently infected healthy donors, followed by transfer to 
patients. At present, there is no reliable strategy to isolate virus-
specific T cells from uninfected naïve individuals, as the precur-
sor frequency is low and the in vitro priming of T-cell responses 
is inefficient. T-cell receptor (TCR) gene transfer offers a strat-
egy to produce antigen-specific T cells independent of precursor 
frequency and without the need for T-cell priming.
Gene modIfICATIon To pRoduCe  
AnTIGen-SpeCIfIC T CellS
Retroviral transfer of chimeric single chain antibody constructs 
(scFv) has been used as a strategy to produce T cells with defined 
antigen-specificity.14 For the most part, chimeric scFv constructs 
were linked to the intracellular signaling domains of FcR-gamma 
or CD3-zeta to trigger T-cell effector function.15 More recently, 
the CD3-zeta domain has been combined with the signaling 
domains of co-stimulatory molecules such as CD28,16–20 4-1BB21 
or OX40.22 In these constructs, antibody engagement can trigger 
effector T-cell function and also deliver co-stimulatory signals. 
An attractive feature of antibody-based receptors is that antigen 
recognition is HLA-independent, whereas TCR recognition is 
HLA-restricted. A disadvantage of antibody receptors is that 
they can only recognize cell surface antigens, whereas TCRs can 
recognize intracellular antigens that are cleaved into peptide 
fragments and presented in the context of major histocompat-
ibility complex class I and class II molecules on the surface of 
antigen-presenting cells or tumor cells.
For a detailed discussion of strategies to improve chimeric 
scFv receptors, we refer to the review by Rossig and Brenner.23 
Here, we will discuss in more detail the challenges related to TCR 
gene therapy.
TCR Gene TRAnSfeR
In the last years, several groups have demonstrated the feasibil-
ity of retroviral TCR gene transfer to produce antigen-specific 
T lymphocytes for adoptive immunotherapy.24–37 Retroviral TCR 
gene transfer was first demonstrated using a melanoma antigen-
specific TCR, although the efficiency was low in these initial 
studies.24 In the last few years, the efficiency of TCR gene trans-
fer has been improved substantially, providing an opportunity 
to produce relatively large numbers of antigen-specific T cells 
rapidly. Detailed analyses demonstrated that the fine specificity 
and the avidity of TCR-transduced CTL is similar to that of the 
parental CTL from which the TCR was isolated.32 In addition, 
murine experiments have demonstrated that adoptive transfer 
of TCR-transduced T cells can protect against virus infection 
and mediate rejection of tumors expressing the TCR-recognized 
antigen.27,36 Recently, the first clinical trial by Rosenberg’s group 
demonstrated that TCR gene-modified T cells can have antitu-
mor effects in melanoma patients.38 In this trial, patient T cells 
were transduced with a retroviral construct encoding the alpha 
and beta chains of a MART1-specific TCR. Fifteen patients 
showed high level engraftment of the TCR-transduced autolo-
gous T cells, and two showed a clinical response. Although this 
milestone study demonstrated the feasibility and potential of 
TCR gene therapy, it also indicated that further modifications 
are required to improve the clinical benefit of this approach.
To date, bulk T-cell populations were used in most TCR gene 
transfer protocols. The polyclonal activation using anti-CD3 
antibodies alone or in combination with anti-CD28 antibodies 
efficiently trigger the proliferation of CD4+ helper T cells and 
CD8+ cytotoxic T cells, rendering them susceptible to retroviral 
infection. It is currently not known to what extent these activation 
protocols also trigger the proliferation of CD4+25+ regulatory 
T cells. In the setting of cancer immunotherapy, TCR gene trans-
fer into regulatory T cells is highly undesirable, as these T cells 
would be expected to suppress the anti-cancer activity of TCR 
gene-modified cytotoxic and helper T cells. The depletion of the 
CD4+25+ T-cell population before retroviral transduction is an 
efficient strategy to minimize the risk associated with TCR gene 
transfer into regulatory T cells.
There is good evidence that for an optimal and efficient 
CTL response help derived from CD4+ T cells is required.39 The 
relative lack of defined epitopes that are recognized by tumor-
reactive helper T cells may limit the ability to provide help for 
effective antitumor immunity. An attractive strategy to over-
come this limitation and to produce tumor-reactive helper T 
cells is by redirecting their specificity using major histocompat-
ibility complex-class I restricted TCR with defined antitumor 
specificity. The feasibility of this approach was demonstrated 
when tumor-reactive helper T cells were generated by retrovi-
ral transduction with major histocompatibility complex-class I 
restricted, CD8-independent TCR.40–43 In contrast, the genera-
tion of tumor-reactive helper T cells using TCR that require the 
function of the CD8 co-receptor requires retroviral co-transfer 
of TCR and CD8 genes.44,45 Although TCR affinity for major his-
tocompatibility complex-class I-peptide complexes can deter-
mine the level of CD8-independence, structural features of TCR 
that are currently poorly understood can also determine CD8-
dependent/independent function.46
opTImIZInG TCR expReSSIon
To date, the majority of TCR gene transfer protocols have used 
retroviral vectors. For efficient infection of human T cells, viral 
particles are usually packaged with amphotropic envelopes or 
with gibbon ape leukemia virus envelopes. For efficient infection 
of mouse T cells, viral particles with ecotropic envelopes are most 
commonly used. However, efficient infection does not necessarily 
lead to efficient expression of the introduced TCR on the surface 
of infected T cells.
TCR alpha and beta chains form heterodimers that require 
association with the CD3 gamma, delta, epsilon, and zeta chains 
before they can be expressed as functional receptor on the cell 
surface of T cells (Figure 1). Without CD3 molecules, TCR alpha/
beta heterodimers cannot assemble properly and are degraded in 
the endoplasmic reticulum.47 As CD3 molecules are required for 
the cell surface expression of the endogenous TCR, there is little or 
no free CD3 available for the introduced TCR. Hence, the endog-
enous and the introduced TCR compete for association with the 
CD3 molecules, which sets a limit to the amount of total TCR that 
can be expressed in transduced T cells.
Frequently, the introduced TCR chains are expressed at lower 
levels than the endogenous TCR (Figure 2), which is a concern as 
it may reduce the ability of transduced T cells to respond to low 
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concentrations of the TCR-recognized antigen. Recent studies 
have demonstrated that the expression levels of the introduced 
TCR can depend on the “strength” of the endogenous TCR.48,49 
TCR transfer into T cells expressing a “strong” TCR resulted in 
poor expression of the introduced TCR, whereas transfer into 
T cells expressing a “weak” TCR resulted in high level expres-
sion of the introduced TCR. At present, the molecular basis that 
determines whether TCR expression on the surface of T cells is 
efficient or inefficient (i.e., whether a TCR is “strong” or “weak”) 
is not clear, although sequences in the variable region of the TCR 
play an important role.48
Poor TCR expression may impair the therapeutic efficacy of 
transduced T cells in adoptive immunotherapy of tumors, as high 
avidity T cells are more likely to control tumor growth than low avid-
ity T cells.50 One parameter that is likely to affect the competitiveness 
of the introduced TCR is the level of expression that can be achieved 
from the retroviral vector. Hence, retroviral vectors designed for 
high levels of gene expression were developed for efficient surface 
expression of human TCR genes in human T lymphocytes.51,52
Surprisingly, murine TCRs were found to be more efficiently 
expressed in human T cells than human TCRs, and hybrid TCR 
constructs demonstrated that the murine constant region was 
responsible for this effect.28 Hybrid TCR constructs (Figure 3) 
were recently exploited to enhance the expression of human 
TCRs that were poorly expressed in human T cells. Replac-
ing the human constant region with murine sequences resulted 
in efficient expression of the hybrid TCR, without altering TCR 
specificity.53 It is likely that this strategy can be employed for all 
poorly expressed human TCRs, while murine constant region 
sequences may be less effective in enhancing the expression of 
well-expressed human TCRs. A drawback of this approach is that 
murine protein sequences are likely to trigger immune responses 
in patients treated with TCR-transduced T cells, which may lead 
to the rejection of the transferred T cells. However, the condition-
ing regimens used to prepare patients for adoptive T-cell therapy,38 
not only causes lymphodepletion but may also result in sufficient 
immunosuppression to allow the engraftment of T cells express-
ing murine sequences.
In a simplistic two-step model of TCR assembly and expression, 
it may be useful to consider the pairing between the TCR alpha 
and beta chains as a first step, the efficacy of which is affected by 
both the constant and the variable TCR domains (Figure 4). The 
association of the paired TCR chains with the CD3 components 
can be considered as the second step, which involves interactions 
between the TCR constant region (including the transmembrane 
and cytosolic portions) and the CD3 molecules. This would pre-
dict that murine TCR constant regions bind to human CD3 mol-
ecules more efficiently than human TCR constant regions, which 
was observed in a recent study of human/murine hybrid TCRs.53
Codon optimization is an alternative strategy to enhance 
the expression of TCR genes. A recent study demonstrated that 
improved expression of human TCR genes can be achieved by 
altering the sequence of rare codons to frequently used codons, 
and by removing messenger RNA instability motifs and cryptic 
splice sites. Human T cells transduced with the optimized genes 
displayed substantially higher TCR expression and improved 
functional activity compared to T cells transduced with the wild 
type sequence.54
Increasing the supply of CD3 molecules is likely to increase 
TCR expression in gene-modified T cells. Recently, it was shown 
that the genes for CD3-gamma, CD3-delta, CD3-epsilon and 
CD3-zeta, linked via 2A self-cleaving sequences, could all be 
figure 1 diagram showing T-cell receptor (TCR) surface expression 
and the interaction with a peptide-presenting major histocompat-
ibility complex (mhC) class I molecule. TCR alpha/beta heterodimers 
associate with the chains of the CD3 complex. This association is essen-
tial for expression of the TCR on the cell surface. The CD3 chains are also 
essential for signal transduction. The red dots represent immunorecep-
tor tyrosine-based activation motifs that can be phosphorylated when 
the TCR recognizes a peptide presented by an MHC molecule.
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figure 2 low T-cell receptor (TCR) expression in gene transduced 
T cells. Human T lymphocytes were mock transduced or transduced with 
a retroviral vector encoding the human TCR Vα1.5 and Vβ2.1 chains. Lym-
phocytes were stained with antibodies specific for human CD8 and Vβ2.1. 
The expression of the endogenous Vβ2.1, indicated in circle 1, is substan-
tially higher than the expression of the introduced TCR chain, indicated 
in circle 2.
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figure 3 T-cell receptor (TCR) constructs to reduce mis-pairing and 
increase surface expression. Human TCRs were modified by replacing 
the constant regions with murine sequences, and by introducing and 
additional disulfide bond into the constant region.
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 endogenous and introduced chains form novel receptors, which 
might display unexpected specificities for self-antigens and 
cause autoimmune damage when transferred into patients. 
Hence, several strategies have been explored to reduce the risk of 
mis-pairing between endogenous and introduced TCR chains. 
The introduction of murine constant region sequences described 
above (Figure 3) not only enhanced the association with CD3 
molecules, but it also decreased the level of mis-pairing with 
TCR chains expressed in Jurkat cells.53 This indicates that 
human/murine hybrid TCR chains with murine constant region 
sequences preferentially pair with each other and have a reduced 
ability to pair with full-length human TCR chains. Interestingly, 
we found that human TCR chains that only differed in the vari-
able region showed large differences in their ability to pair with 
human/murine hybrid chains. This shows that the TCR variable 
region has an important role in TCR alpha/beta pairing, and 
it also indicates that the murine constant region only reduces 
the frequency of mis-pairing, rather than eliminating this risk 
 completely.
Mutations of the TCR alpha/beta interface is an alternative 
strategy to reduce unwanted mis-pairing. For example, the intro-
duction of an additional cysteine in the constant domains of the 
alpha and beta chain (Figure 3) allowed the formation of an addi-
tional disulfide bond and enhanced the pairing of the mutant 
chains while reducing the efficiency of pairing with wild type 
chains.58 Again, the reduction of pairing is not absolute, as a sub-
stantial number of wild type TCR chains can still pair with the 
cysteine mutant chains.
The generation of single chain TCR constructs is a strategy 
that can completely eliminate mis-pairing between endogenous 
and introduced TCR chains. Although single chain TCR mole-
cules have been produced and are expressed in transduced T cells, 
they tend to be functionally impaired as suggested by the increased 
peptide concentrations required for stimulation of T cells express-
ing a single chain TCR construct compared with a normal TCR 
alpha/beta heterodimer.59
TCR TRAnSfeR InTo STem CellS
The transfer of TCR alpha and beta genes into hematopoietic 
stem cells offers an attractive strategy that can lead to the pro-
duction of mature T cells that express only the introduced TCR 
and no additional endogenous TCR chains.60–62 Gene transfer 
into hematopoietic stem cells does not lead to TCR expression on 
the cell surface as stem cells do not express the CD3 molecules. 
However, when stem cells differentiate into lymphoid precur-
sors that migrate to the thymus, the initiation of CD3 expression 
leads to the surface expression of the introduced TCR in thy-
mocytes. The expression of functional TCR chains suppresses, 
by a mechanism called allelic exclusion, the rearrangement of 
endogenous TCR gene segments to form functional TCR alpha 
and beta genes. Although allelic exclusion is not complete, it is 
expected to impair the formation of endogenous TCR chains 
allowing a proportion of developing T cells to express only the 
TCR genes that were introduced into the stem cells. This would 
decrease the risk of TCR mis-pairing and also increase surface 
expression of the introduced TCR as it does not compete for 
CD3 molecules with the endogenous TCR (Figure 5).
accommodated in one retroviral vector. This vector drives the 
expression of CD3 chains that were able to associate with TCR 
chains to form a functional receptor on the surface of infected 
cells.55 Although it is possible to express four genes encoding CD3 
components from a single retroviral vector, it is very difficult to 
achieve equimolar expression levels of each chain or to mimic 
the relative expression levels of endogenous CD3 chains. Never-
theless, co-transfer of the genes for the CD3 chains and the TCR 
chains should improve TCR surface expression by alleviating the 
fierce competition between endogenous and introduced TCR for 
limited amounts of CD3.
Interestingly, there is evidence that reduced amounts of the 
CD3-zeta chain in patients with chronic infection and cancer can 
impair T-cell function.56,57 Hence, it is conceivable that CD3-zeta 
is a rate-limiting factor in TCR assembly and that co-transfer of 
the gene for this chain is sufficient to improve TCR expression in 
gene-modified T cells.
A combination of the strategies described above is possibly 
required for optimal TCR expression in human T cells. For exam-
ple, sequence optimization to enhance the levels of protein expres-
sion combined with the introduction of murine constant region 
sequences to enhance the efficiency of CD3 association may 
work synergistically and allow introduced TCRs to compete with 
endogenous TCR successfully for expression on the cell surface. 
In this scenario, the expression of additional CD3 molecules in 
gene-modified T cells would further benefit the introduced TCR 
and improve its surface expression.
ReduCInG TCR mIS-pAIRInG
TCR gene transduced T cells express at least two TCR alpha 
and two TCR beta chains. While the endogenous TCR alpha/
beta chains form a receptor that is self-tolerant, the introduced 
TCR alpha/beta chains form a receptor with defined specific-
ity for a tumor target antigen. However, mis-pairing between 
figure 4 Schematic diagram of T-cell receptor (TCR) assembly. In this 
simplistic model, the efficiency of TCR expression is determined by the 
efficiency of TCR alpha/beta heterodimer formation (step 1), and by the 
efficiency of the TCR heterodimer to assemble with CD3 chains (step 2). 
Fully assembled TCR/CD3 complexes are released from the endoplasmatic 
reticulum (ER) and migrate to the cell surface (step 3).
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The introduced TCR is responsible for further T-cell differ-
entiation in the thymus, which involves positive selection pro-
vided the TCR can recognize self-antigens with low affinity. It 
also involves negative selection, which triggers deletion of devel-
oping T cells if the TCR recognizes self-antigens with high affin-
ity. Therefore, mature T cells derived from TCR gene transduced 
stem cells express a validated TCR that is functional and free of 
auto-reactivity. A further benefit of this approach is that the gene-
modified stem cells are a continuous source of mature T cells with 
defined antigen-specificity. A disadvantage of this approach is 
that TCRs with specificity for tumor-associated antigens may get 
deleted during T-cell development in the thymus, or may induce 
tolerance when expressed in peripheral T cells. This is because 
tumor-associated antigens represent normal self-proteins that are 
expressed in some normal tissues, which may include the thymus 
and/or peripheral tissues. Another disadvantage of this approach 
is the risk of retroviral insertional mutagenesis in stem cells. Inser-
tional mutagenesis has been implicated in the development of 
T-cell leukemia in 4 out of 20 children treated for X-linked severe 
combined immunodeficiency disease by retroviral transfer of the 
gene encoding the interleukin-2 (IL-2) receptor common gamma 
chain into hematopoietic stem cells.63–65 Proviral integration in the 
LMO2 locus, leading to up-regulation of LMO2 expression con-
tributed to leukemogenesis in all affected patients. Whether the 
common gamma chain itself contributed to the development of 
T-cell leukemias is still under debate.66–68
To date, no side effects related to insertional mutagenesis 
in clinical trials with gene-modified mature T cells have been 
reported. A recent study showed that retroviral integration pat-
tern in mature T cells is different from that in stem cells.69 A 
follow-up of patients treated with retrovirus transduced T cells 
showed that the transferred cells displayed normal T-cell func-
tion in vivo, with no evidence of clonal selection 9 years after 
T-cell infusion.69 These observations suggests that retroviral 
transduction of mature T cells is relatively safe, although larger 
trials are required to judge the risk more accurately.
Recent murine studies have clearly shown that TCR gene trans-
fer into stem cells is an effective strategy to produce mature T cells 
that are functionally active, and that can protect against tumors 
expressing an “artificial” model antigen that is not expressed in 
any normal tissue.61,62 TCR gene transfer into stem cells and dif-
ferentiation into T cells can also be achieved in vitro.70 Although 
the functional activity of such in vitro generated T cells has not 
yet been fully tested, this provides a strategy to avoid thymic and 
peripheral tolerance induction with TCRs that are specific for 
tumor-associated antigens.
AvoIdInG in vitro T-Cell ACTIvATIon
Retroviral gene transfer involves T-cell activation and prolif-
eration, usually achieved with anti-CD3 antibodies alone or in 
combination with anti-CD28 antibodies. This extensive in vitro 
stimulation triggers T-cell differentiation into effector cells, which 
is associated with a loss of expression of certain chemokine recep-
tors and adhesion molecules that are involved in T-cell migration 
to lymphoid tissues. The lack of homing to lymphoid tissues is 
associated with a reduced ability of adoptively transferred T cells 
to control tumor growth in murine model experiments.71 Hence, 
it is desirable to limit in vitro T-cell activation and to produce 
gene-modified T cells that can migrate to lymphoid tissues when 
injected into patients.
The antibody stimulation protocol used for retroviral trans-
duction can trigger the down-regulation of the chemokine recep-
tor CCR7 and the adhesion molecule CD62L, both of which are 
involved in T-cell migration to lymphoid tissues. Recently, it was 
demonstrated that the cytokines IL-15 and IL-21 can maintain the 
expression of CD62L in activated human T cells.72 Therefore, it is 
possible that the addition of these cytokines to retroviral trans-
duction protocols may generate transduced T cells with higher 
levels expression of lymphoid homing molecules, which would 
be expected to improve their therapeutic efficacy after adoptive 
transfer into patients.
An alternative strategy is to infect resting, non-proliferating 
T cells. This is achievable with lentiviral vectors, which can infect 
human T cells without the need for full activation and prolifera-
tion. Although quiescent human T cells were not infected with 
lentiviral vectors, T cells exposed to IL-2 and IL-7 progressed 
from G0 to G1, which rendered the cells susceptible to infection 
with lentiviral vectors containing the green fluorescent protein 
marker.73 Infection did not require cell proliferation and did not 
alter the phenotype of the gene-modified T cells. Although lenti-
viral vectors containing TCR genes have not yet been successfully 
used to direct TCR expression in the absence of T-cell activation, 
this is an attractive strategy to produce TCR gene-modified T lym-
phocytes with minimal changes of the T-cell phenotype. Although 
fully activated effector T cells are less effective in providing tumor 
protection than less differentiated T cells,71 it is not clear if mini-
mally activated naïve T cells, transduced with a lentiviral TCR 
figure 5 The concept of T-cell receptor (TCR) validation by gene 
transfer into stem cells. TCR gene transduced hematopoietic stem cells 
(HSC) in the bone marrow can express the TCR chains inside the cell, 
but not on the surface due to lack of CD3 molecules. CD3 expression 
in the thymus results in TCR surface expression, followed by positive 
and negative selection, which results in T-cell deletion if the TCR fails 
to interact with major histocompatibility complex (MHC) or recognizes 
self-antigens with high affinity. Selected T cells migrate to the periphery 
where encounter of self-antigens that are not expressed in the thymus 
may lead to deletion or the induction of anergy. Functional mature T 
cells are generated when the TCR has successfully completed all selec-
tion steps and is therefore able to interact with self-MHC without high 
avidity recognition of peptides derived from self-antigens.
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construct, are effective when adoptively transferred in vivo. It is 
possible that lentiviral transduction of central memory T cells is 
a more promising approach, as this T-cell population has proven 
potential for long-term in vivo survival and is more easily acti-
vated by antigen than naïve T cells.
few TCR CAn SeRve A lARGe pATIenT 
populATIon
To date, most proof of principle studies were performed with TCR 
that recognize tumor-derived peptides in the context of HLA-
A*02. This HLA allele was selected by most investigators because 
of its prevalence of 40–50% in the Caucasian population. We 
have explored how many TCR with defined HLA-restriction are 
the frequency of 5 HLA-A locus alleles, HLA-A*01, A*02, A*03, 
A*11 and A*24 in individuals of the north European Caucasoid 
population. These 5 alleles are found in 89.7% of individuals, indi-
cating that a relatively small set of 5 TCR restricted by these alleles 
would provide a panel of therapeutic reagents for the majority of 
patients. If successful, TCR gene therapy will need to target sev-
eral epitopes in one patient, which will reduce the risk of tumor 
most desirable to use TCR gene therapy in the adjuvant setting 
in patients with minimal tumor burden following conventional 
therapy. T-cell control of small numbers of tumor cells is expected 
to be more effective than control of large tumors, which are likely 
to contain variant tumor cells that can resist T-cell attack.
ConCluSIon
The first TCR gene therapy trial in patients was recently com-
pleted, demonstrating the feasibility of this approach. In the near 
future, additional trials with TCRs of different specificities in 
different disease settings will provide valuable information 
about the potential benefits and the risks of this approach. TCR 
mis-pairing resulting in accidental recognition of self-antigens 
remains a risk, which can be reduced by modifications of the TCR 
sequences. An attractive option to reduce the risk associated with 
mis-pairing is the transfer of TCR genes into hematopoietic stem 
cells. The drawback of this approach is the increased risk of inser-
tional mutagenesis of stem cells, which can give rise to leukemia. 
Co-transfer of TCR genes together with suicide genes is a possible 
strategy of risk management, allowing selective elimination of the 
gene modified cells when unwanted side effects occur. The devel-
opment of optimized TCR constructs that can be safely delivered 
into minimally manipulated T lymphocytes holds great promise 
for antigen-specific adoptive T-cell therapy.
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